Increased arterial stiffness and the presence of metabolic syndrome (MS) have been shown to predict cardiovascular events in patients with primary hypertension. We investigated the relationship between a recently proposed index of arterial stiffness derived from ambulatory blood pressure (BP) monitoring and MS in 156 untreated, non-diabetic patients with primary hypertension. Ambulatory arterial stiffness index (AASI) was defined as 1 minus the regression slope of diastolic over systolic BP readings obtained from 24-h recordings. A modified National Cholesterol Education Program definition for MS was used, with body mass index replacing waist circumference. The prevalence of MS was 23%. Patients with MS were more frequently male (0.0291) and had increased serum uric acid (P ¼ 0.0005), high-sensitivity C-reactive protein (P ¼ 0.0259), as well as total and low-density lipoprotein (LDL)-cholesterol (P ¼ 0.0374 and P ¼ 0.0350, respectively) as compared to those without MS. After adjusting for these confounders, the association between AASI and the presence of MS was statistically significant (P ¼ 0.0257). Moreover, the prevalence of increased AASI (upper tertile, that is X0.550) was greater in patients with MS (P ¼ 0.0156). After adjusting for age and 24-h mean BP, the presence of MS entailed a more than twofold greater risk for increased AASI (0.0280). MS is associated with increased AASI in non-diabetic patients with primary hypertension. These data support the role of this new index of arterial stiffness as a marker of risk and help to explain the high cardiovascular morbidity and mortality that is observed in hypertensive patients with MS.
Introduction
Metabolic syndrome (MS) is characterized by a cluster of metabolically related, well-known cardiovascular risk factors such as hypertension, obesity, insulin resistance and atherogenic dyslipidaemia. Several epidemiological studies demonstrated that the presence of MS as a whole leads to a worse cardiovascular prognosis, exceeding, at least in part, the risk that is attributable to each one of its individual components. 1 Large-artery stiffening is associated with several cardiovascular risk factors and represents an independent predictor of cardiovascular disease. [2] [3] [4] [5] A new, easy to obtain index, which is derived from ambulatory blood pressure (BP) recordings, has been recently proposed as an indicator of arterial stiffness and has been shown to provide information on the presence of subclinical hypertensive organ damage as well as on cardiovascular mortality. [6] [7] [8] It was previously reported that MS is independently associated with pulse-wave velocity, a classic way of measuring arterial stiffness. 9, 10 This finding suggests that a decrease in the compliance of the arterial system may account for the excess of cardiovascular disease observed in patients with MS as compared to those without it.
Currently, no data are available regarding the relationship between MS and ambulatory arterial stiffness index (AASI). This study was therefore devised to investigate whether MS was associated with AASI in a group of never previously treated, non-diabetic patients with primary hypertension.
Materials and methods

Study population
Between June 2003 and January 2006, all untreated patients with primary hypertension attending the outpatient clinic of our institution were asked to participate in this study, which was part of a larger trial (MAGIC, Microalbuminuria: A Genoa Investi-gation on Complications) approved by the ethics committee of our department. 11 Inclusion criteria included office BP X140/90 mm Hg on at least two visits and absence of secondary causes of hypertension. Exclusion criteria were the presence of neoplastic and/or hepatic diseases, serum creatinine 4124 mmol/l for women and 4133 mmol/l for men, proteinuria 4300 mg/24 h, chronic heart failure (New York Heart Association class III and IV), positive history or clinical signs of ischaemic heart disease, diabetes mellitus, severe obesity (defined as body mass index (BMI) X35 kg/m 2 ), disabling diseases such as dementia or inability to cooperate, high-sensitivity C-reactive protein (hs-CRP) 410 mg/l (a value that is commonly used to represent clinically relevant inflammation), treatment with hypolipidaemic agents, and any condition influencing the technical quality of ambulatory BP monitoring, such as atrial fibrillation and other major dysrhythmias. Altogether, 183 patients (all Caucasian Europeans) from a total of 232 hypertensive patients seen at our clinic within the above-mentioned time range fulfilled the inclusion criteria. After written informed consent had been obtained, all patients underwent the following procedures: (1) office BP measurement; (2) 24-h ambulatory BP monitoring; (3) standard questionnaire to assess history and lifestyle habits; (4) blood and urine sampling; and (5) standard 12-lead electrocardiogram.
One hundred and fifty-six of the enrolled patients completed the study and had good technical quality 24-h ambulatory BP monitoring. Of the participating patients, 139 (89%) had never been treated for hypertension, whereas 17 (11%) had received antihypertensive treatment in the past, albeit intermittently and not during the 6 months before the study. On the study day, after an overnight fast, height and weight were measured and venous blood was obtained for routine biochemical investigations. BMI was calculated by the formula weight (kg)/ height 2 (m 2 ). Creatinine clearance was estimated by the Cockcroft-Gault formula. 12 Ideal body weight was used in the formula. Low-density lipoprotein (LDL)-cholesterol was calculated using Friedewald et al.'s formula. 13 Hs-CRP was measured by nephelometry on an Immage Immunochemistry System (Beckman Coulter Inc., Fullerton, CA, USA) using the manufacturer's reagent. The lower detection limit for hs-CRP was 0.06 mg/l. The intra-and inter-assay coefficients of variation for this parameter were o5%. Family history and lifestyle habits were assessed by means of a standard questionnaire. Smoking status was defined as current use.
Blood pressure measurement Office BP was measured by a trained nurse, with the patient in the sitting position after a 5-min rest, with a mercury sphygmomanometer using an appropriate-sized cuff. The systolic blood pressure (SBP) and diastolic blood pressure (DBP) were read to the nearest 2 mm Hg. Disappearance of Korotkoff's sounds (phase V) was the criterion for DBP. The mean of three consecutive readings was used in the statistical analysis.
The 24-h ambulatory BP monitoring was carried out on the non-dominant arm using an oscillometric device (Spacelabs 90207; SpaceLabs Inc., Redmond, WA, USA) and an appropriate-sized cuff. The device was set to obtain BP readings every 15 min during the daytime (0700-2300) and every 30 min during the night time (2300-0700). The mean BP (MBP) was computed as follows: 2/3 DBP þ 1/3 SBP.
AASI AASI was calculated as 1 minus the regression slope of DBP plotted against SBP obtained from individual 24-h BP measurements. 6 The slope was not forced through the origin. The rationale underlying the concept of AASI is that the relationship between DBP and SBP is dynamic during the day and depends largely on the functional and structural characteristics of large arteries. In particular, in the presence of arterial stiffness, DBP varies less for a given amount of change in SBP, resulting in a lower regression slope and consequently, in a higher AASI.
Increased AASI was defined as the highest tertile of the values among the study patients, which was equal to or more than 0.550.
Metabolic syndrome
Patients were classified by the presence or absence of the MS, on the basis of a modified National Cholesterol Education Program criteria.
14 As waist circumference data were not available for the whole study group, it was replaced by BMI. A BMI X28.5 kg m À2 in men and X26.3 kg m À2 in women was considered evidence of central obesity. These cutoff values were equivalent to a waist circumference of 102 cm in men and 88 cm in women in a regression analysis performed on a subgroup of 94 patients. The remaining cutoff values were as follows: serum triglyceride levels X1.70 mmol/l; serum high-density lipoprotein (HDL)-cholesterol o1.03 mmol/l in men and o1.30 mmol/l in women; fasting plasma glucose X5.6 mmol/l, as modified from 6.1 mmol/l, according to the 2003 report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 15 As all patients were hypertensives, only two additional factors from the aforementioned risk factors were necessary for the definition of MS.
Statistical analysis
All data are expressed as arithmetic mean7standard deviation (s.d.) or median (interquartile range) for skewed variables. Variables found to deviate from normality were log-transformed before the statistical analyses were carried out. Comparisons between groups were made by analysis of variance or w 2 test, as appropriate. Relations among variables were assessed by using linear regression analysis and the Pearson correlation coefficient (r). Odds ratios (OR) and 95% confidence intervals (CI) were calculated by exponentiation of logistic regression coefficients. Three multivariate models were used to assess the association between AASI and MS as a whole, as well as between AASI and the individual components of MS. The first included the presence or absence of MS, and the second included each of the individual components of MS, without including MS itself. The third model included both the individual components of MS and MS itself. All statistical analyses were performed with the use of Statview for Windows (SAS Institute Inc., version 5.0.1). A value of Po0.05 was considered statistically significant.
Results
The main clinical characteristics of the study patients are reported in Table 1 . The overall prevalence of MS was 23% (n ¼ 36). Within the entire study group, the prevalence of the various components of MS was as follows: BP level X130/ X85 mm Hg 100% (n ¼ 156) by selection, glycaemia X5.6 mmol/l 26.3% (n ¼ 41), increased BMI 28.2% (n ¼ 44), triglycerides X1.7 mmol/l 21.2% (n ¼ 33) and HDL-cholesterol o1.03 mmol/l in men and o1.30 mmol/l in women 19.2% (n ¼ 30). A total of 41.7% (n ¼ 65), 16.0% (n ¼ 25) and 7.1% (n ¼ 11) had one, two or three traits of MS, respectively, in addition to being hypertensive.
By definition, all the anthropometric and metabolic variables used to define MS were significantly different between the two groups. Furthermore, patients with MS were more frequently male (0.0291) and had higher serum uric acid (P ¼ 0.0005), hs-CRP levels (P ¼ 0.0259), and total and LDL-cholesterol (P ¼ (Figure 1) .
Univariate analysis showed that AASI was positively related to age (r ¼ 0.152, P ¼ 0.0410) and 24-h SBP (r ¼ 0.196, P ¼ 0.0139). In order to assess the relationship between AASI and MS as a whole, as well as between AASI and each of the individual components of MS, logistic regression analysis was performed. MS was the only variable associated with increased AASI in a model that included among independent variables age and 24-h MBP. The presence of MS entailed a more than twofold higher risk of having increased AASI (Table 2 , model 1). When MS was replaced by its individual components that were entered into the model simultaneously, triglycerides level turned out to be the only independent variable associated with higher AASI (Table 2 , model 2).
When MS was included in multivariate analysis together with its individual components, only triglycerides level proved to be independently related to increased AASI (Table 3) .
Discussion
This study demonstrates that MS is associated with increased AASI. This finding is independent of potentially confounding factors, such as age and BP levels, which are positively related to AASI, and gender, serum uric acid, hs-CRP and LDLcholesterol, which characterize patients with MS, besides the anthropometric and metabolic variables that are used to define MS itself. An independent association between MS and arterial stiffness as measured by various techniques including pulse-wave velocity and arterial distensibility has already been described in cross-sectional studies, especially in middle-aged and elderly patients. 16, 17 More recently, Safar et al. 18 demonstrated that the presence of MS entails an increased progression of age-related arterial stiffness, thus fostering an acceleration of the ageing process. The novelty of our findings resides in the fact that this is the first evidence of the association between MS and AASI, a recently proposed index of arterial stiffness. Evaluation of this new parameter requires neither specific equipment nor specially trained personnel. In fact, AASI can easily be derived from ambulatory BP monitoring, a technique that is increasingly being used in the management of hypertensive patients, and, therefore, could be performed on a large scale in clinical practice.
This index has been shown to be independently associated with the presence of subclinical, hypertensive organ damage as well as cardiovascular mortality. 7, 8 Therefore, the increased AASI we observed in patients with MS may provide a rationale for the excess of atherosclerotic cardiovascular disease reported in patients with MS. The results of multiple logistic regression analysis in this hypertensive group indicate that MS entails a greater risk of increased AASI than each one of its five components (Table 2) . Therefore, it could be hypothesized that the adverse effect that MS has on arterial stiffness could exceed what is attributable to its individual components and may be due to other, unmeasured variables such as pro-inflammatory state, endothelial dysfunction, hyperactivity of the sympathetic nervous system and the renin-angiotensin system that are often concomitant with the syndrome. [19] [20] [21] [22] These factors may alter vascular tone and promote hypertrophy of vascular smooth muscle cells and collagen synthesis in the arterial wall, thereby influencing arterial compliance. However, some authors disagree that MS itself conveys additional cardiovascular risk beyond the contribution of its components 23, 24 and results of the model of multiple logistic regression analysis when MS was included together with its individual components are in accord with this hypothesis (Table 3) . Unfortunately, owing to the cross-sectional design of our study, we cannot draw conclusions in terms of causal relationships among our findings. However, on the basis of our results, we may speculate on the potential mechanisms underlying the association between MS and AASI. Subclinical, low-grade inflammation and hyperuricaemia are frequently associated with several components of MS as well as with functional and structural alterations of the arterial bed. [25] [26] [27] [28] [29] [30] Nevertheless, in this study, the relationship between arterial stiffness and MS was independent of hs-CRP and uric acid. As for gender influence, patients with MS were more frequently male; however, AASI levels were higher in these patients regardless of gender. Moreover, the correlation between AASI and MS we observed appears to be especially strong when one considers that it was independent of established risk factors for arterial stiffness. In fact, patients with diabetes mellitus and severe obesity were excluded from our study by selection criteria, and the excess of arterial stiffness we observed in patients with the MS was independent of BP levels and age (Table 2) .
We acknowledge that the validity of AASI as a measure of arterial stiffness has been questioned, 31, 32 since it represents only an indirect estimate of the mechanical properties of arterial walls. Nonetheless, recent studies have suggested that AASI has a prognostic value even beyond traditional risk factors. [6] [7] [8] 33, 34 Thus, evaluation of AASI could become an important diagnostic tool, provided further clinical and experimental studies confirm and ultimately validate it.
In conclusion, this study provides the first evidence that regardless of its individual components, MS is associated with AASI in non-diabetic, untreated patients with primary hypertension. The finding that MS is related to arterial stiffness, even when measured by means of ambulatory BP monitoring, may account for the worse cardiovascular outcome described in patients with MS. Furthermore, our results could have practical, clinical implications in risk-assessment strategies. In fact, these data integrate previous reports on the relationship between AASI and cardiovascular risk, and support the usefulness of evaluating this new, easily obtainable index of arterial stiffness in the assessment of patients' global risk status.
What is known about this topic K Increased arterial stiffness and the presence of metabolic syndrome (MS) have been shown to predict cardiovascular events in patients with primary hypertension. K The association between MS and direct measures of arterial stiffness, such as aortic pulse-wave velocity, has been established. K Currently, no data are available regarding the relationship between MS and ambulatory arterial stiffness index (AASI), a recently proposed indicator of arterial stiffness easily derived from ambulatory blood pressure monitoring.
What this study adds K This study confirms the relationship between MS and arterial stiffness and, in particular, provides the first evidence that the presence of MS entails a greater risk of higher AASI in nondiabetic, untreated patients with primary hypertension. K The association between MS and AASI is independent of potentially confounding factors. Furthermore, MS as a whole entails a greater risk of higher AASI than each one of its components. K These findings support the usefulness of evaluating this new, easily obtainable index of arterial stiffness in the assessment of patients' global risk status, provided further clinical and experimental studies confirm and ultimately validate it.
